Navigation Links
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Date:2/25/2009

te, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

    Factors that may cause actual results to differ materially from current
    expectations include, but are not limited to:
        -- our ability to obtain necessary financing in the near term;
        -- our ability to control our operating expenses;
        -- our ability to recruit and enroll pa
'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Mass. , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic ... of Robert Bazemore as Chief Operating ... , President and Chief Executive Officer, Robert will ... company,s lead program, sebelipase alfa for LAL Deficiency, ...
(Date:9/21/2014)... have discovered how to produce ultra-thin "diamond nanothreads" that ... that of today,s strongest nanotubes and polymers. A paper ... John V. Badding, a professor of chemistry at Penn ... 2014 issue of the journal Nature Materials . ... is intriguing because the threads we formed have a ...
(Date:9/20/2014)... Austin, Texas (PRWEB) September 20, 2014 ... of integrated urological and interventional radiology products and ... Endocare, Inc. subsidiary with Clinicon Corporation ... addition expands HealthTronics’ portfolio of minimally invasive, mobile, ... their patients. , Under the agreement, HealthTronics will ...
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2
... , , , ... IDIX ), a biopharmaceutical company engaged in the discovery ... today announced the pricing of an underwritten offering of 7,248,936 shares ... After underwriting discounts and commissions and estimated offering expenses, the company ...
... HALIFAX, NS, Aug. 5 /PRNewswire/ - ImmunoVaccine Technologies ... signed an agreement with UK-based Scancell Ltd., the ... is developing therapeutic cancer and infectious disease vaccines. ... using IVT,s DepoVax(TM) delivery system for Scancell,s novel ...
... ... Park, Fla., will demonstrate how its partnership with AeroClave, LLC, can help stop the ... mitigate the threat of healthcare-associated infections such as MRSA and contagious pathogens including H1N1 ... ...
Cached Biology Technology:Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock 2ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery 2Winter Park Home to World's Foremost Producers of Large-Scale Decontamination Equipment 2
(Date:9/22/2014)... a key molecular cog in a plant,s biological clock ... rhythms based on temperature. , Transcription factors, or genetic ... stresses such as light, rain, soil quality, or ... at USC has isolated one, called FBH1, that reacts ... as needed while in keeping it on a consistent ...
(Date:9/22/2014)... is one of seven institutions in the country ... to receive this year,s BEST Award a ... the university,s most promising biomedical sciences graduate trainees ... path that they have traditionally taken. , The ... Opportunities for Biomedical Scientists (iJOBs) program. It includes ...
(Date:9/22/2014)... (September 22, 2014) Additive manufacturing (AM), or ... the production of complex-shaped metal components strong enough ... fewer errors and distortions, as well as quality ... kept pace with the technology. Engineers at the ... proposing to develop enhanced modeling and simulation (M&S) ...
Breaking Biology News(10 mins):Genetic switch regulates a plant's internal clock based on temperature 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3
... Brazil are more susceptible to toxoplasmosis than those in ... in Austria, Brazil, Denmark, France, Italy, Poland, Sweden, ... in children from birth to four years of age. ... journal PLoS Neglected Tropical Diseases . ...
... the body regulates blood pressure in response to daily ... helping people whose pressure is out of control. ... pressure is not controlled despite the best efforts of ... director of the Georgia Prevention Institute at the Medical ...
... of Angelman syndrome, a neurological disorder that causes mental ... births, has been developed by biologists at The University ... when a particular fruit fly gene, dube3a, is altered, ... experienced by humans whose UBE3A gene doesn,t function normally. ...
Cached Biology News:Blood pressure response to daily stress provides clues for better hypertension treatment 2Blood pressure response to daily stress provides clues for better hypertension treatment 3Blood pressure response to daily stress provides clues for better hypertension treatment 4Blood pressure response to daily stress provides clues for better hypertension treatment 5Blood pressure response to daily stress provides clues for better hypertension treatment 6Model for angelman syndrome developed by University of Texas at Austin biologists 2
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: